Is Exenatide approved as a medicine, and where?

It is an approved prescription medicine, but where it is approved matters: FDA (United States; Byetta, initial approval 2005). It should only be used under medical supervision.

What is Exenatide studied for?

Exenatide is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.

Does Exenatide have human clinical trials?

Yes. Exenatide has been studied in human clinical trials and is an approved medicine in at least some regions.

Index by category›

Metabolic & Weight Loss

Exenatide

Byetta; synthetic exendin-4

1 min read · Updated July 27, 2026 · 3 references

Curated by PeptideInfo Wikilast reviewed July 27, 2026how we verify

Explored forApproved peptide medicines — verification pilot

In brief · TL;DR

Approved medicine· US

An approved GLP-1 receptor agonist for glycemic control in adults with type 2 diabetes.

Evidence: Regulator-approved drug with human trial evidence.

Approved in: FDA (United States; Byetta, initial approval 2005)

An approved GLP-1 receptor agonist for glycemic control in adults with type 2 diabetes.
It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion and slowing gastric emptying.
The FDA label warns about pancreatitis, dehydration-related kidney injury, severe gastrointestinal reactions, hypoglycemia with insulin or secretagogues, and immune-mediated thrombocytopenia.

↓ Read the full referenced entry below

An approved GLP-1 receptor agonist for glycemic control in adults with type 2 diabetes.

Contents4

Section 1 of 4Overview

Overview

An approved GLP-1 receptor agonist for glycemic control in adults with type 2 diabetes.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Section 2 of 4Identity and mechanism

Identity and mechanism

It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion and slowing gastric emptying.

PubChem CID 45588096; C184H282N50O60S; 4187 Da.

Section 3 of 4Regulatory label facts

Regulatory label facts

FDA (United States; Byetta, initial approval 2005).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Byetta: 5 micrograms subcutaneously twice daily within 60 minutes before the two main meals; the label permits an increase to 10 micrograms twice daily after one month based on clinical response.

Section 4 of 4Safety boundary

Safety boundary

The FDA label warns about pancreatitis, dehydration-related kidney injury, severe gastrointestinal reactions, hypoglycemia with insulin or secretagogues, and immune-mediated thrombocytopenia.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

References3

References

1.
Exenatide — Primary regulatory source source
2.
Exenatide — PubChem compound record source
3.
Exenatide — Human study source

Frequently asked questions4

Frequently asked questions

What is Exenatide?: An approved GLP-1 receptor agonist for glycemic control in adults with type 2 diabetes.
Is Exenatide approved as a medicine, and where?: It is an approved prescription medicine, but where it is approved matters: FDA (United States; Byetta, initial approval 2005). It should only be used under medical supervision.
What is Exenatide studied for?: Exenatide is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
Does Exenatide have human clinical trials?: Yes. Exenatide has been studied in human clinical trials and is an approved medicine in at least some regions.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Exenatide is an approved medicine within the stated approval scope (FDA (United States; Byetta, initial approval 2005)) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.

Overview

Identity and mechanism

Regulatory label facts

Safety boundary

References

Frequently asked questions

Related in Metabolic & Weight Loss